# Title

 Food and Drugs. PART 56â€”INSTITUTIONAL REVIEW BOARDS


# ID

 CFR-2018-title21-vol1.Pt. 56


# Structured Analysis Summary

| Type        | Values                                                                                                       |
|:------------|:-------------------------------------------------------------------------------------------------------------|
| Constraints | ['before', 'within', 'less than', 'lesser', 'after', 'greater', 'at least', 'no more than']                  |
| Duration    | ['30.0 day', '1.0 year', '12.0 month', '2.0 minute', '90.0 day', '3.0 year']                                 |
| Condition   | ['until', 'not subject to', 'unless', 'where', 'if not', 'subject to', 'provided that', 'when', 'if']        |
| Entities    | ['Test', 'United States', 'Scope', 'Public', 'Agriculture', 'Food', 'Rm', 'Lesser', 'Health', 'Cooperative'] |
| Date        | ['1981-07-27', '2001-04-30']                                                                                 |


# Structured Analysis With Context

 


## Constraints

| Constraints   | Context                                                                                                                |
|:--------------|:-----------------------------------------------------------------------------------------------------------------------|
| greater       | or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered       |
| within        | reviewed and may be conducted at an institution within the constraints set forth by the IRB and                        |
| before        | for IRB review: (a) Any investigation which commenced before July 27, 1981 and was subject to requirements             |
| before        | for IRB review: (a) Any investigation which commenced before July 27, 1981 and was subject to requirements             |
| before        | for IRB review: (a) Any investigation which commenced before July 27, 1981 and was subject to requirements             |
| before        | (b) Any investigation commenced  before July 27, 1981 and was not otherwise subject                                    |
| before        | (b) Any investigation commenced  before July 27, 1981 and was not otherwise subject                                    |
| within        | such emergency use is reported to the IRB within  5 working days.                                                      |
| before        | The initial registration must occur  before the IRB begins to review a clinical investigation                          |
| after         | IRB registration becomes effective  after  review and acceptance by HHS.                                               |
| within        | information by submitting any changes in that information within  90 days of the change.                               |
| within        | FDA is a change that must be reported within  30 days of the change.                                                   |
| within        | disband is a change that must be reported within 30 days of permanent cessation of the IRB's                           |
| at least      | (a) Each IRB shall have  at least five members, with varying backgrounds to promote complete                           |
| at least      | (c) Each IRB shall include  at least one member whose primary concerns are in the                                      |
| at least      | (c) Each IRB shall include  at least one member whose primary concerns are in the                                      |
| at least      | (d) Each IRB shall include  at least one member who is not otherwise affiliated with                                   |
| at least      | the members of the IRB are present, including at least one member whose primary concerns are in nonscientific          |
| no more than  | form if it finds that the research presents no more than minimal risk of harm to subjects and involves                 |
| less than     | appropriate to the degree of risk, but not less than once per year, and shall have authority to                        |
| no more than  | review procedures for certain kinds of research involving no more than minimal risk, and for minor changes in approved |
| no more than  | list and found by the reviewer(s) to involve no more than minimal risk, (2) minor changes in previously approved       |
| after         | A research activity may be disapproved only  after review in accordance with the nonexpedited review procedure         |
| within        | policy) as among those research risks that fall within  the purview of its responsibility.                             |
| at least      | required by this regulation shall be retained for at least 3 years after completion of the research, and               |
| after         | shall be retained for at least 3 years after completion of the research, and the records shall                         |
| lesser        | Lesser administrative actions. lesser                                                                                  |
| within        | or the parent institution respond to this letter within a time period specified by FDA and describe                    |
| before        | in addition to or in lieu of, and before , at the time of, or after, disqualification.                                 |
| after         | of, and before, at the time of, or after , disqualification.                                                           |


## Duration

| Duration   | Context                                                                                                                                                                                                                                                                                                                                                                        |
|:-----------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 12.0 month | For purposes of this rule, an &#8220;active protocol&#8221; is any protocol for which an IRB conducted an initial review or a continuing review at a convened meeting or under an expedited review procedure during the preceding 12 months; and                                                                                                                               |
|            |               (4) A description of the types of FDA-regulated products (such as biological products, color additives, food additives, human drugs, or medical devices) involved in the protocols that the IRB reviews.                                                                                                                                                         |
| 3.0 year   | Each IRB must renew its registration every 3 years.                                                                                                                                                                                                                                                                                                                            |
| 90.0 day   | If an IRB's contact or chair person information changes, the IRB must revise its registration information by submitting any changes in that information within 90 days of the change.                                                                                                                                                                                          |
| 30.0 day   | An IRB's decision to review new types of FDA-regulated products (such as a decision to review studies pertaining to food additives whereas the IRB previously reviewed studies pertaining to drug products), or to discontinue reviewing clinical investigations regulated by FDA is a change that must be reported within 30 days of the change.                              |
| 30.0 day   | An IRB's decision to disband is a change that must be reported within 30 days of permanent cessation of the IRB's review of research.                                                                                                                                                                                                                                          |
| 1.0 year   | (b) An IRB may use the expedited review procedure to review either or both of the following: (1) Some or all of the research appearing on the list and found by the reviewer(s) to involve no more than minimal risk, (2) minor changes in previously approved research during the period (of 1 year or less) for which approval is authorized.                                |
| 2.0 minute | (2) Minutes of IRB meetings which shall be in sufficient detail to show attendance at the meetings; actions taken by the IRB; the vote on these actions including the number of members voting for, against, and abstaining; the basis for requiring changes in or disapproving research; and a written summary of the discussion of controverted issues and their resolution. |
| 3.0 year   | (b) The records required by this regulation shall be retained for at least 3 years after completion of the research, and the records shall be accessible for inspection and copying by authorized representatives of the Food and Drug Administration at reasonable times and in a reasonable manner.                                                                          |


## Condition

| Condition      | Context                                                                                                                 |
|:---------------|:------------------------------------------------------------------------------------------------------------------------|
| unless         | Regulations are to chapter I of title 21, unless  otherwise noted.                                                      |
| when           | about a clinical study of an infant formula when submitted as part of an infant formula notification                    |
| subject to     | color additive, electronic product, or any other article subject to regulation under the act or under sections 351      |
| unless         | Food and Drug Administration shall not be initiated unless that investigation has been reviewed and approved by,        |
| subject to     | has been reviewed and approved by, and remains subject to continuing review by, an IRB meeting the requirements         |
| not subject to | has not been approved by, and that was not subject to initial and continuing review by, an IRB meeting                  |
| subject to     | which commenced before July 27, 1981 and was subject to requirements for IRB review under FDA regulations before        |
| provided that  | IRB review under FDA regulations before that date, provided that the investigation remains subject to review of an      |
| subject to     | which commenced before July 27, 1981 and was subject to requirements for IRB review under FDA regulations before        |
| subject to     | before July 27, 1981 and was not otherwise subject to requirements for IRB review under Food and Drug                   |
| provided that  | (c) Emergency use of a test article,  provided that such emergency use is reported to the IRB                           |
| subject to     | of the test article at the institution is subject to  IRB review.                                                       |
| if             | and food quality evaluations and consumer acceptance studies, if  wholesome foods without additives are consumed or     |
| if             | and food quality evaluations and consumer acceptance studies, if  wholesome foods without additives are consumed or     |
| when           | (c) When must an IRB register? when                                                                                     |
| where          | (d) Where can an IRB register? where                                                                                    |
| when           | All other information changes may be reported  when  the IRB renews its registration.                                   |
| where          | be initiated without IRB review and approval except where necessary to eliminate apparent immediate hazards to the      |
| when           | (c) Except  when an expedited review procedure is used (see &#167;&#8201;56.110),                                       |
| when           | mentioned in &#167;&#8201;50.25, be given to the subjects when in the IRB's judgment the information would meaningfully |
| if             | legally authorized representative, sign a written consent form if it finds that the research presents no more           |
| where          | (d) In cases  where the documentation requirement is waived under paragraph (c)(1)                                      |
| when           | the investigator and the sponsor of the research when an IRB determines that it cannot approve the                      |
| when           | time of its initial review of the research. when                                                                        |
| when           | or IRB's use of the expedited review procedure when necessary to protect the rights or welfare of                       |
| if             | subjects are reasonable in relation to anticipated benefits, if any, to subjects, and the importance of the             |
| if not         | benefits of therapies that subjects would receive even if not  participating in the research).                          |
| where          | data collected to ensure the safety of subjects. where                                                                  |
| where          | subjects and to maintain the confidentiality of data. where                                                             |
| when           | protect the rights and welfare of these subjects. when                                                                  |
| subject to     | has been approved by an IRB may be subject to further appropriate review and approval or disapproval by                 |
| if             | However, those officials may not approve the research  if  it has not been approved by an IRB.                          |
| where          | (a) An institution, or  where appropriate an IRB, shall prepare and maintain adequate                                   |
| if             | (1) Copies of all research proposals reviewed, scient if ic evaluations,                                                |
| if             | an application for a research or marketing permit if the institution or the IRB that reviewed the                       |
| if             | observations to an appropriate representative of the IRB. if                                                            |
| until          | In addition,  until the IRB or the parent institution takes appropriate                                                 |
| subject to     | IRB to: (1) Withhold approval of new studies subject to the requirements of this part that are conducted                |
| subject to     | IRB to: (1) Withhold approval of new studies subject to the requirements of this part that are conducted                |
| subject to     | IRB to: (1) Withhold approval of new studies subject to the requirements of this part that are conducted                |
| when           | (3) Terminate ongoing studies subject to this part when  doing so would not endanger the subjects.                      |
| when           | the deficiencies in the operation of the IRB. when                                                                      |
| if             | (b) The Commissioner may disqual if y an IRB or the parent institution                                                  |
| if             | (c) If the Commissioner determines that disqual if ication is appropriate, the Commissioner will issue an               |
| unless         | disqualified IRB as conducted at a disqualified institution, unless the IRB or the parent institution is reinstated     |
| if             | An IRB or an institution may be reinstated  if the Commissioner determines, upon an evaluation of a                     |


## Entities

| Entities      | Context                                                                                                                        |
|:--------------|:-------------------------------------------------------------------------------------------------------------------------------|
| Food          | Food  and Drugs.                                                                                                               |
| Scope         | Scope .                                                                                                                        |
| Test          | (l)  Test article means any drug for human use, biological                                                                     |
| Agriculture   | and Inspection Service of the U.S. Department of Agriculture .                                                                 |
| United States | Each IRB in the  United States that reviews clinical investigations regulated by FDA under                                     |
| United States | Each IRB in the  United States that reviews clinical investigations regulated by FDA under                                     |
| Health        | at a site maintained by the Department of Health  and Human Services (HHS).                                                    |
| Rm            | 32,  Rm .                                                                                                                      |
| Cooperative   | Cooperative  research.                                                                                                         |
| Lesser        | Lesser  administrative actions.                                                                                                |
| Food          | the agency under &#167;&#8201;56.120(a), and the Commissioner of Food and Drugs determines that this noncompliance may justify |
| Public        | Public  disclosure of information regarding revocation.                                                                        |


## Date

| Date       | Context                                                                                                                                                                                                                                                                                                   |
|:-----------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1981-07-27 | The following categories of clinical investigations are exempt from the requirements of this part for IRB review:                                                                                                                                                                                         |
|            |               (a) Any investigation which commenced before July 27, 1981 and was subject to requirements for IRB review under FDA regulations before that date, provided that the investigation remains subject to review of an IRB which meets the FDA requirements in effect before July 27, 1981.      |
| 1981-07-27 | The following categories of clinical investigations are exempt from the requirements of this part for IRB review:                                                                                                                                                                                         |
|            |               (a) Any investigation which commenced before July 27, 1981 and was subject to requirements for IRB review under FDA regulations before that date, provided that the investigation remains subject to review of an IRB which meets the FDA requirements in effect before July 27, 1981.      |
| 1981-07-27 | (b) Any investigation commenced before July 27, 1981 and was not otherwise subject to requirements for IRB review under Food and Drug Administration regulations before that date.                                                                                                                        |
| 2001-04-30 | When some or all of the subjects in a study that was ongoing on April 30, 2001, are children, an IRB must conduct a review of the research to determine compliance with part 50, subpart D of this chapter, either at the time of continuing review or, at the discretion of the IRB, at an earlier date. |


